US 12,280,056 B2
Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
James Russell Lipford, Thousand Oaks, CA (US); Jude Robert Canon, Newbury Park, CA (US); Anne Y. Saiki, Moorpark, CA (US); and Karen Louise Rex, Thousand Oaks, CA (US)
Assigned to Amgen Inc., Thousand Oaks, CA (US)
Filed by Amgen Inc., Thousand Oaks, CA (US)
Filed on Dec. 19, 2023, as Appl. No. 18/545,932.
Application 18/545,932 is a continuation of application No. 17/870,573, filed on Jul. 21, 2022, granted, now 11,918,584.
Application 17/870,573 is a continuation of application No. 16/687,563, filed on Nov. 18, 2019, granted, now 11,439,645, issued on Sep. 13, 2022.
Claims priority of provisional application 62/865,819, filed on Jun. 24, 2019.
Claims priority of provisional application 62/821,376, filed on Mar. 20, 2019.
Claims priority of provisional application 62/769,355, filed on Nov. 19, 2018.
Prior Publication US 2024/0245686 A1, Jul. 25, 2024
Int. Cl. A61P 35/00 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/555 (2006.01); C07K 16/28 (2006.01)
CPC A61K 31/519 (2013.01) [A61P 35/00 (2018.01); A61K 31/555 (2013.01); C07K 16/2818 (2013.01)] 37 Claims
 
1. A method of treating cancer mediated by a KRAS G12C mutation in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2-methyl-4-(prop-2-enolyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H-one, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an EGFR inhibitor, wherein the cancer is non-small cell lung cancer, small intestine cancer, appendix cancer, colorectal cancer, endometrial cancer, pancreatic cancer, skin cancer, gastric cancer, nasal cavity cancer, or bile duct cancer.